The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine

• Published in: Vaccines (Basel) Vol. 10; no. 4; p. 536
• Main Authors: Mahasirimongkol, Surakameth, Khunphon, Athiwat, Kwangsukstid, Oraya, Sapsutthipas, Sompong, Wichaidit, Mingkwan, Rojanawiwat, Archawin, Wichuckchinda, Nuanjun, Puangtubtim, Wiroj, Pimpapai, Warangluk, Soonthorncharttrawat, Sakulrat, Wanitchang, Asawin, Jongkaewwattana, Anan, Srisutthisamphan, Kanjana, Phainupong, Daraka, Thawong, Naphatcha, Piboonsiri, Pundharika, Sawaengdee, Waritta, Somsaard, Thitiporn, Ritthitham, Kanokphon, Chumpol, Supaporn, Pinyosukhee, Nadthanan, Wichajarn, Rattanawadee, Dhepakson, Panadda, Iamsirithaworn, Sopon, Phumiamorn, Supaporn
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.03.2022; MDPI
• Subjects: Adverse events; Antibodies; Cell culture; Coronaviruses; COVID-19 vaccine; COVID-19 vaccines; Enrollments; heterologous; heterologous prime-boost; homologous; Homology; Immunization; Immunogenicity; Immunoglobulin G; Immunoglobulins; inactivated; Influenza; Laboratories; Neutralization; Priming; Public health; Safety; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Spike protein; Vaccines; Thailand; United States > US; Ireland; inactivated; COVID-19 vaccine; heterologous; adenoviral vector; heterologous prime-boost; immunogenicity; homologous

In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford−AstraZeneca), a prime−boost vaccine regimen. This pil...